Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
about
SERCA2 Haploinsufficiency in a Mouse Model of Darier Disease Causes a Selective Predisposition to Heart FailureA mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.Septic cardiomyopathy in rat LPS-induced endotoxemia: relative contribution of cellular diastolic Ca(2+) removal pathways, myofibrillar biomechanics properties and action of the cardiotonic drug levosimendan.Mitochondrial pathways to cardiac recovery: TFAM.
P2860
Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@en
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@nl
type
label
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@en
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@nl
prefLabel
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@en
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@nl
P2093
P2860
P1476
Long-term levosimendan treatme ...... disruption of the Serca2 gene.
@en
P2093
Andreas Knorr
Frank Kramer
Kristin B Andersson
Stefan Golz
Vigdis Hillestad
P2860
P304
P356
10.1152/JAPPLPHYSIOL.01044.2012
P407
P577
2013-09-26T00:00:00Z